Active Ingredient History
Talazoparib (BMN 673) demonstrates excellent potency, inhibiting PARP1 and PARP2 enzyme activity. It inhibits PARP-mediated PARylation in a whole-cell assay and prevents proliferation of cancer cells carrying mutant BRCA1/2. Talazoparib is orally available, displaying favorable pharmacokinetic properties and remarkable antitumor efficacy in the BRCA1 mutant MX-1 breast cancer xenograft model following oral administration as a single-agent or in combination with chemotherapy agents such as temozolomide and cisplatin. Medivation (a subsidiary of Pfizer) is developing talazoparib (MDV 3800, formerly BMN 673 and LT 673) for the treatment of genetically defined cancers. On October 16, 2018, the FDA approved talazoparib (TALZENNA, Pfizer Inc.) for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2‑negative locally advanced or metastatic breast cancer. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Breast Neoplasms (approved 2018)
BRCA1 Protein (Phase 2)
Breast Neoplasms (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Ovarian Epithelial (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 3)
Colorectal Neoplasms (Phase 2)
Endometrial Neoplasms (Phase 2)
Esophageal Neoplasms (Phase 1)
Fallopian Tube Neoplasms (Phase 2)
Gene Expression (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Hamartoma (Phase 2)
Healthy Volunteers (Phase 1)
Hemangiosarcoma (Phase 2)
Hepatoblastoma (Phase 1/Phase 2)
Kidney Neoplasms (Phase 1/Phase 2)
Leukemia (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia, Myeloid, Acute (Phase 1/Phase 2)
Lung Neoplasms (Phase 2)
Lyme Disease (Phase 2)
Lymphoma (Phase 3)
Lymphoma, Mantle-Cell (Phase 1)
Melanoma (Phase 2)
Mesothelioma (Phase 1)
Mutation (Phase 3)
Myelodysplastic Syndromes (Phase 1)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 3)
Neoplasms, Germ Cell and Embryonal (Phase 1/Phase 2)
Neuroblastoma (Phase 1/Phase 2)
Neuroectodermal Tumors (Phase 1/Phase 2)
Neuroendocrine Tumors (Phase 1)
Osteosarcoma (Phase 1/Phase 2)
Ovarian Diseases (Early Phase 1)
Ovarian Neoplasms (Phase 3)
Pancreatic Neoplasms (Phase 2)
Paraganglioma (Phase 2)
Pheochromocytoma (Phase 2)
Prostatic Neoplasms (Phase 3)
PTEN Phosphohydrolase (Phase 2)
Rhabdoid Tumor (Phase 1/Phase 2)
Rhabdomyosarcoma (Phase 1/Phase 2)
Sarcoma (Phase 1/Phase 2)
Sarcoma, Ewing (Phase 1/Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 1)
Vaginal Neoplasms (Phase 1)
Wilms Tumor (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
